Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Implitapide is an inhibitor of microsomal triglyceride transfer protein (MTP).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,570.00 | |
50 mg | 10-14 weeks | $ 3,380.00 | |
100 mg | 10-14 weeks | $ 4,600.00 |
Description | Implitapide is an inhibitor of microsomal triglyceride transfer protein (MTP). |
In vitro | Implitapide inhibits MTP activity using a recombinant human form complexed with protein disulphide isomerase (IC50=10 nM). Implitapide also inhibits the secretion of apoB-containing very low-density lipoprotein (VLDL)-like lipoproteins from a human hepatoma cell (HepG2) (IC50: 1.1 nM)[1]. |
In vivo | Administering Implitapide (3.2 mg/kg/d) significantly inhibits lipid-stained lesions in mice on a Western-type diet (WD), reducing lesion area by 83% compared to the WD group (p<0.01) and substantially lowering plasma lipid levels to near or below those on a chow diet (CD) at both 4 and 8 weeks of treatment (p<0.01). Furthermore, this dosage of Implitapide markedly reduces lipid-stained aortic lesions by 83% in apoE knockout (KO) mice. In addition, apoE KO mice fed a WD supplemented with varying doses of Implitapide (1, 5, and 15 mg/kg/d) for 14 weeks exhibit a significant decrease in both plaque area (66, 78, and 93% reduction, respectively) and lipid content within plaques (to 4.3, 2.6, and 0%, respectively, compared with 9.5% in controls)[1]. |
Synonyms | AEGR 427 |
Molecular Weight | 531.69 |
Formula | C35H37N3O2 |
CAS No. | 177469-96-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Implitapide 177469-96-4 Metabolism CETP AEGR427 AEGR 427 AEGR-427 inhibitor inhibit